Abstract 5865
Background
The 21-gene Breast Recurrence Score® (RS) is an established genomic tool to assess recurrence risk and adjuvant chemotherapy benefit in early breast cancer. The TAILORx study redefined group boundaries of the RS in node negative women. In the 668 patients of the NSABP-B14 study that formed the validation set of the RS younger age was significantly correlated with distant recurrence and tumour size trended toward significance. High tumour grade remained an independent prognostic factor beyond the RS. In the TAILORx study these higher risk groups were under-represented.
Methods
We compared clinical prognostic parameters of women in South East London with available RS with the TAILORx trial population. Retrospective case note analysis of all identified patients between 2013 and 2018 was completed. Women with nodal involvement were excluded. Descriptive statistics were used for comparison with patient characteristics of the TAILORx study.
Results
A total of 269 tests were identified. 42 were excluded for nodal involvement or incomplete clinical data, leaving 227 patients. Differences between the populations are demonstrated for all characteristics and will be presented at the meeting.Table:
263P Patient characteristic
RS | <11 | 11-25 | >26 | ALL |
N (%) | 34 (11) | 142 (67) | 51 (22) | 227 (100) |
Median age (range) | 48 (28-75) | 49 (28-74) | 53 (38-78) | 50 (28-78) |
≤50 yr % | 56 | 56 | 41 | 52 |
Premenopausal % | 59 | 64 | 47 | 59 |
Tumour size in cm Median (IQR) Mean (SD) | 2.0 (1.7-3.0) 2.6 ± 1.5 | 2.1 (1.5-3.0) 2.6 ± 1.8 | 2.2 (1.6-3.0) 2.4 ± 1.2 | 2.1 (1.6-3.0) 2.6 ± 1.6 |
Tumour grade % Low Intermediate High | 6 74 21 | 4 63 33 | 0 24 76 | 4 56 41 |
Clinical risk % Low High High (TAILORx) | 35 65 22 | 32 68 26 | 20 80 57 | 30 70 |
Conclusions
Our patients have a higher clinical risk than the TAILORx population. They are younger and have larger, higher grade cancers. This population is under-represented in the TAILORx study which was unable to exclude benefit in the ≤ 50 subset and may thus underestimate benefit from chemotherapy in our population. The current RS reporting is biased towards an older, low-risk population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Gousis: Travel / Accommodation / Expenses: Roche. H. Kristeleit: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Advisory / Consultancy: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
4331 - STING Agonist, ADU-S100, Yields Potent Antitumor Activity and Therapeutically Favorable Immune Profile in an Esophageal Adenocarcinoma Model
Presenter: Ali Zaidi
Session: Poster Display session 2
Resources:
Abstract
1770 - Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract
3755 - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.
Presenter: Roberto Labianca
Session: Poster Display session 2
Resources:
Abstract
2439 - The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry
Presenter: Tae-yong Kim
Session: Poster Display session 2
Resources:
Abstract
2211 - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
Presenter: Yelena Janjigian
Session: Poster Display session 2
Resources:
Abstract
3046 - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)
Presenter: Tao Fu
Session: Poster Display session 2
Resources:
Abstract
4628 - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?
Presenter: Inês Oliveira
Session: Poster Display session 2
Resources:
Abstract
2127 - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Presenter: Yu Sunakawa
Session: Poster Display session 2
Resources:
Abstract
2264 - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
Presenter: Masanori Terashima
Session: Poster Display session 2
Resources:
Abstract
2444 - Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in Oesophageal adenocarcinoma
Presenter: Emma Ococks
Session: Poster Display session 2
Resources:
Abstract